Isryl-M 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Isryl-M 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage appropriately and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis associated with Metformin. Patients should be advised to report any unusual symptoms promptly. This combination therapy offers a convenient and effective option for optimizing glycemic control in type 2 diabetes patients.